# Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer

> **NCT04806464** · PHASE1 · RECRUITING · sponsor: **CNBG-Virogin Biotech (Shanghai) Ltd.** · enrollment: 44 (estimated)

## Conditions studied

- Primary Liver Cancer

## Interventions

- **DRUG:** Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell))

## Key facts

- **NCT ID:** NCT04806464
- **Lead sponsor:** CNBG-Virogin Biotech (Shanghai) Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-03-16
- **Primary completion:** 2022-03-21
- **Final completion:** 2024-12-31
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04806464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04806464, "Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04806464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*